Company profile: Diagnomics
1.1 - Company Overview
Company description
- Provider of NGS-based genomics solutions for personalized medicine and next-generation healthcare, offering high-quality R&D and CLIA services including whole genome, exome and RNA sequencing, microarray services, bioinformatics analysis, and clinical/translational research support.
Products and services
- Whole Genome Sequencing: Engineers NGS-based complete DNA sequence analysis across the entire genome, pinpointing genetic variations for research programs and personalized medicine applications
- RNA Sequencing: Produces transcriptome-wide quantification and sequence profiling of RNA in defined samples to study gene expression patterns and regulatory dynamics
- Exome Sequencing: Architects sequencing of the genome’s protein-coding regions, discovering genetic influences on disease using a protein-coding focused approach to variant detection
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Diagnomics
DropWorks
HQ: United States
Website
- Description: Provider of instrumentation and analytical techniques using novel continuous flow droplet nanoreactors, focused on digital PCR that delivers absolute nucleic acid quantification and ultra-high sensitivity through a simple, high-throughput, low-cost workflow, enabling multiplexed analysis without standard NB curves or pipeline replicates pipelines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DropWorks company profile →
Sividon Diagnostics
HQ: Germany
Website
- Description: Provider of advanced diagnostics that facilitate therapeutic discovery, focused on improving the quality of companion diagnostics in oncology to support future cancer treatment decisions; based in Cologne, Germany, and formed via a management buyout from Siemens Healthcare Diagnostics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sividon Diagnostics company profile →
Envisagenics
HQ: United States
Website
- Description: Provider of AI/ML-driven RNA sequencing analysis solutions to accelerate therapeutic development. Offers SpliceCore, a platform that analyzes RNA splicing events to discover drug targets, and SpliceIO, a machine learning module that identifies RNA splicing-derived neoepitopes for immunotherapy, reducing biomedical data complexity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Envisagenics company profile →
BrainVectis
HQ: France
Website
- Description: Provider of gene therapies for neurodegenerative and other diseases, aiming to restore brain cholesterol metabolism by increasing CYP46A1 for Huntington’s and Alzheimer’s. Offerings include AB-1005 delivering GDNF to the brain for Parkinson’s, ACT-101 delivering GAA to the liver for Late-Onset Pompe Disease, and NAN-101 activating I-1c to inhibit PP1 for NYHA Class III heart failure.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BrainVectis company profile →
GB HealthWatch
HQ: United States
Website
- Description: Provider of digital health solutions advancing genetic tests for preventive health, including GBinsight NGS-based genetic testing and actionable analysis for complex cardiometabolic diseases (type 2 diabetes, dyslipidemia, obesity, coronary heart disease); the HealthWatch 360 app for personalized nutrition, diet/exercise/symptom tracking; the HealthWatch 360 Research Portal for study data; and integrated nutritional genomics analysis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GB HealthWatch company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Diagnomics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Diagnomics
2.2 - Growth funds investing in similar companies to Diagnomics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Diagnomics
4.2 - Public trading comparable groups for Diagnomics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →